Ald-Ph-NHS ester structure
|
Common Name | Ald-Ph-NHS ester | ||
---|---|---|---|---|
CAS Number | 60444-78-2 | Molecular Weight | 247.204 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 425.4±47.0 °C at 760 mmHg | |
Molecular Formula | C12H9NO5 | Melting Point | 163ºC | |
MSDS | Chinese USA | Flash Point | 211.1±29.3 °C |
Use of Ald-Ph-NHS esterAld-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC). |
Name | N-Succinimidyl p-Formylbenzoate |
---|---|
Synonym | More Synonyms |
Description | Ald-Ph-NHS ester is a nonclaevable linker for antibody-drug-conjugation (ADC). |
---|---|
Related Catalog | |
Target |
Noncleavable |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 425.4±47.0 °C at 760 mmHg |
Melting Point | 163ºC |
Molecular Formula | C12H9NO5 |
Molecular Weight | 247.204 |
Flash Point | 211.1±29.3 °C |
Exact Mass | 247.048065 |
PSA | 80.75000 |
LogP | -0.20 |
Vapour Pressure | 0.0±1.0 mmHg at 25°C |
Index of Refraction | 1.606 |
Storage condition | -20°C |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
RIDADR | NONH for all modes of transport |
HS Code | 2925190090 |
~99% Ald-Ph-NHS ester CAS#:60444-78-2 |
Literature: Quinton, Julia; Kolodych, Sergii; Chaumonet, Manon; Bevilacqua, Valentina; Nevers, Marie-Claire; Volland, Herve; Gabillet, Sandra; Thuery, Pierre; Creminon, Christophe; Taran, Frederic Angewandte Chemie - International Edition, 2012 , vol. 51, # 25 p. 6144 - 6148 |
~% Ald-Ph-NHS ester CAS#:60444-78-2 |
Literature: Organic and Biomolecular Chemistry, , vol. 8, # 19 p. 4329 - 4345 |
Precursor 3 | |
---|---|
DownStream 0 |
HS Code | 2925190090 |
---|---|
Summary | 2925190090 other imides and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0% |
PSMA-specific theranostic nanoplex for combination of TRAIL gene and 5-FC prodrug therapy of prostate cancer.
Biomaterials 80 , 57-67, (2016) Metastatic prostate cancer causes significant morbidity and mortality and there is a critical unmet need for effective treatments. We have developed a theranostic nanoplex platform for combined imagin... |
|
A strategy for the systematic development of a liquid chromatographic mass spectrometric screening method for polymer electrolyte membrane degradation products using isocratic and gradient phase optimized liquid chromatography.
J. Chromatogr. A. 1216 , 8910-8917, (2009) Within the scope of research for target and non-target LC-MS/MS analysis of membrane degradation products of polymer electrolyte membrane fuel cells, a systematic method development for the separation... |
|
Synthesis of pH-sensitive amphotericin B-poly(ethylene glycol) conjugates and study of their controlled release in vitro.
Bioorg. Med. Chem. 15 , 4069-4076, (2007) New intravenous conjugates of amphotericin B (AMB) with poly(ethylene glycols) (PEG) (M=5000, 10,000, 20,000) have been synthesized and characterised. The intermediate PEGs possess a 1,4-disubstituted... |
Benzaldehyde, 4-[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]- |
(2,5-dioxopyrrolidin-1-yl) 4-formylbenzoate |
4-{[(2,5-Dioxo-1-pyrrolidinyl)oxy]carbonyl}benzaldehyde |